Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Results From a First-in-Human Study of BNZ-1, a Selective Multicytokine Inhibitor Targeting Members of the Common Gamma (γc) Family of Cytokines.
Journal: Journal of clinical pharmacology
Published: July 10, 2019
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 26, 2018
RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
Journal: Gastroenterology
Published: July 19, 2018
Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.
Journal: Clinical pharmacology in drug development
Published: August 08, 2017
Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.
Journal: Clinical pharmacology in drug development
Published: May 15, 2017
Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
Journal: Journal of clinical pharmacology
Published: December 28, 2016
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
Journal: The New England journal of medicine
Published: May 05, 2016
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Journal: The Lancet. Neurology
Published: September 03, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026